Following the May meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) it was announced that three new marketing authorizations could not be recommended.
The CHMP adopted a negative opinion for Switzerland-based cancer specialist Helsinn Group's Adlumiz (anamorelin hydrochloride). Adlumiz was expected to be used to treat anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer.
The Committee adopted a negative opinion for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha Xilonix. This medicine, from USA-based XBiotech (Nasdaq: XBIT) was intended to treat debilitating symptoms of advanced colorectal cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze